
================================================================================
 CASE STUDY ANALYSIS - COMPREHENSIVE TEST (ALL 5 TABS)
================================================================================
  Drug: BARICITINIB
  Started: 2025-12-04 20:05:42.460124
  Output will be saved to: test_outputs\workflow_test_20251204_200542.txt

Initializing agent...
Agent ready.


================================================================================
 TAB 1: DRUG INFO FOR 'BARICITINIB'
================================================================================

  Drug Name:    baricitinib
  Generic Name: baricitinib
  Mechanism:    Janus Kinase Inhibitor
  Manufacturer: Eli Lilly and Company

  Approved Indications (4):
    1. adults with severe alopecia areata
    2. covid-19 in certain hospitalized adults
    3. adults with moderately-to-severely active rheumatoid arthritis
    4. moderately-to-severely active rheumatoid arthritis

--- Validation ---
  PASS: generic_name populated
  PASS: mechanism concise: 'Janus Kinase Inhibitor'
  PASS: Found 4 indications

================================================================================
 TAB 2: CASE SERIES SEARCH FOR 'BARICITINIB'
================================================================================

  Drug: baricitinib
  Exclude: ['adults with severe alopecia areata', 'covid-19 in certain hospitalized adults', 'adults with moderately-to-severely active rheumatoid arthritis']...

Searching... (may take 1-2 mins)

--- Results: 45 papers ---
  Full text (PMC): 22
  LLM verified: 45

  Diseases (38):
    - vitiligo: 3
    - atopic dermatitis: 3
    - juvenile idiopathic arthritis: 2
    - adult-onset Still's disease: 2
    - systemic lupus erythematosus: 2
    - multiple dermatologic conditions: 1
    - dermatomyositis: 1
    - giant cell arteritis: 1
    - type I interferonopathies: 1
    - uveitis: 1
    - folliculitis decalvans: 1
    - SAPHO syndrome: 1
    - polymyalgia rheumatica and giant cell arteritis: 1
    - dystrophic epidermolysis bullosa: 1
    - juvenile idiopathic arthritis-associated uveitis: 1

--- Sample Papers ---

  1. Oral tofacitinib, baricitinib and upadacitinib monotherapy for steroid...
     PMID: 38853646 | Disease: vitiligo
     Full text: False
     Why: Prospective case series with patient outcomes for steroid-resistant vitiligo...

  2. Off-Label Use of Janus Kinase Inhibitors in Inflammatory Cutaneous Dis...
     PMID: 38051858 | Disease: multiple dermatologic conditions
     Full text: False
     Why: Case series with 6 patients showing efficacy outcomes in dermatomyositis, hidrad...

  3. JAK inhibitors in refractory dermatomyositis: A case series....
     PMID: 38887110 | Disease: dermatomyositis
     Full text: False
     Why: Retrospective cohort study of 14 patients with efficacy data showing CDASI score...

  4. Clinical experience and safety of Janus kinase inhibitors in giant cel...
     PMID: 37304255 | Disease: giant cell arteritis
     Full text: True
     Why: Retrospective case series of 15 patients with efficacy data showing CRP reductio...

  5. Janus Kinase Inhibitors in the Treatment of Type I Interferonopathies:...
     PMID: 35418997 | Disease: type I interferonopathies
     Full text: True
     Why: Case series assessing efficacy and safety in type I interferonopathies including...

--- Validation ---
  PASS: Found 45 papers
  WARN: 2 potentially irrelevant papers
    - Janus kinase inhibition for the treatment of refra...
    - Pharmacokinetics, Pharmacodynamics, and Proposed D...

================================================================================
 TAB 3: DATA EXTRACTION (WITH PMC FULL TEXT)
================================================================================

  Extracting from 22 papers with PMC full text...
  (This may take several minutes)

  1. [PMC] Clinical experience and safety of Janus kinase inhibito...
     PASS: Disease=Giant Cell Arteritis, N=15, Response=73.0%
     Efficacy: JAK inhibitors showed significant anti-inflammatory effects with reduced CRP and...
     Safety: Two patients experienced serious infections but JAK inhibitor therapy was retain...

  2. [PMC] Janus Kinase Inhibitors in the Treatment of Type I Inte...
     WARN: No data extracted

  3. [PMC] Case report: Effectiveness of Janus kinase inhibitors i...
     PASS: Disease=isolated noninfectious uveitis, N=3, Response=100.0%
     Efficacy: All three patients with refractory isolated noninfectious uveitis achieved compl...
     Safety: No significant side effects observed in any patients. One patient had a slight t...

  4. [PMC] A Case Report of JAK Inhibitors Therapy for Adult-Onset...
     PASS: Disease=Adult-onset Still's disease with persistent pruritic lesions, N=1, Response=100.0%
     Efficacy: JAKi treatment provided rapid and sustained clinical improvement with complete r...
     Safety: Treatment was well-tolerated with only minor renal function abnormalities noted ...

  5. [PMC] Use of Baricitinib in a patient with treatment-resistan...
     PASS: Disease=pyoderma gangrenosum, N=1, Response=100.0%
     Efficacy: Baricitinib 4 mg daily with tapering prednisone led to resolution of axillary an...
     Safety: Patient developed septic arthritis of the right knee after discontinuing baricit...

  6. [PMC] Janus kinase inhibition for the treatment of refractory...
     PASS: Disease=Frontal Fibrosing Alopecia (FFA), N=1, Response=100.0%
     Efficacy: Complete resolution of perifollicular scale/erythema and pruritus within 1 month...
     Safety: No adverse events reported during 2-month treatment course. Patient tolerated tr...

  7. [PMC] Mixed results with baricitinib in biological-resistant ...
     PASS: Disease=Adult-onset Still's disease (AOSD) and undifferentiated systemic autoinflammatory disease, N=3, Response=67.0%
     Efficacy: Mixed results with baricitinib in biological-resistant AOSD. Two of three patien...
     Safety: One patient developed Pneumocystis jirovecii pneumonia at 7 months, which respon...

  8. [PMC] Assessment of Clinical Response to Janus Kinase Inhibit...
     PASS: Disease=Familial chilblain lupus with TREX1 mutation, N=3, Response=100.0%
     Efficacy: All 3 patients showed significant improvement of cutaneous lupus lesions with su...
     Safety: No severe adverse reactions were reported during the 3-month treatment period. T...

  9. [PMC] Rheumatological complaints in H syndrome: from inflamma...
     PASS: Disease=H syndrome, N=1, Response=None%
     Efficacy: Baricitinib monotherapy provided only partial improvement in arthralgias and wal...
     Safety: No adverse events were reported during the treatment period. The patient tolerat...

  10. [PMC] Off-label use of Baricitinib improves moderate and seve...
     PASS: Disease=atopic dermatitis, N=23, Response=None%
     Efficacy: Baricitinib significantly improved clinical symptoms in moderate-to-severe atopi...
     Safety: No significant toxicities were reported during the 4-week treatment period. The ...

  11. [PMC] Baricitinib restrains the immune dysregulation in patie...
     WARN: No data extracted

  12. [PMC] Alopecia Areata Following the Use of Belimumab in a Pat...
     PASS: Disease=Systemic Lupus Erythematosus, N=1, Response=100.0%
     Efficacy: Patient showed significant improvement in alopecia universalis within 1 month, w...
     Safety: No adverse events reported during baricitinib treatment. Patient was able to tap...

  13. [PMC] JAK1/2 inhibition with baricitinib in the treatment of ...
     PASS: Disease=Monogenic IFN-mediated autoinflammatory diseases, N=None, Response=None%
     Efficacy: Baricitinib was used to ameliorate disease in patients with monogenic IFN-mediat...
     Safety: Safety outcomes not reported in the provided abstract....

  14. [PMC] Disease flares with baricitinib dose reductions and dev...
     PASS: Disease=CANDLE/PRAAS (Chronic Atypical Neutrophilic Dermatosis with Lipodystrophy and Elevated Temperature/Proteasome-Associated Autoinflammatory Syndrome), N=10, Response=50.0%
     Efficacy: Baricitinib demonstrated significant efficacy in CANDLE/PRAAS with 50% of patien...
     Safety: Higher baricitinib exposures required for CANDLE/PRAAS treatment were associated...

  15. [PMC] Sustained Interferon Signature Suppression With Anifrol...
     PASS: Disease=STING-Associated Vasculopathy with Onset in Infancy (SAVI), N=1, Response=None%
     Efficacy: Baricitinib alone at recommended doses failed to adequately control disease with...
     Safety: Significant JAK inhibitor-related side effects occurred including viral reactiva...

  16. [PMC] Pharmacokinetics, Pharmacodynamics, and Proposed Dosing...
     PASS: Disease=CANDLE and SAVI (Mendelian interferonopathies), N=18, Response=None%
     Efficacy: Dose-dependent decreases in interferon biomarkers confirmed in vivo effect of ba...
     Safety: No specific safety outcomes reported in this pharmacokinetic/pharmacodynamic stu...

  17. [PMC] Combination of Baricitinib and Phototherapy in Adults W...
     PASS: Disease=vitiligo, N=49, Response=None%
     Efficacy: Baricitinib combined with narrowband UV-B phototherapy showed significant improv...
     Safety: Safety outcomes were not detailed in the provided abstract, though the study ass...

  18. [PMC] Rapid response of lichen planus to baricitinib associat...
     PASS: Disease=Cutaneous lichen planus, N=12, Response=83.3%
     Efficacy: 83.3% of patients achieved treatment response with PGA scores of 0-3 and 50% or ...
     Safety: Total of 12 adverse events, only one mild AE probably related to study drug (neu...

  19. [PMC] Efficacy and safety of baricitinib in Japanese patients...
     PASS: Disease=Autoinflammatory type I interferonopathies (NNS/CANDLE, SAVI, AGS), N=9, Response=None%
     Efficacy: Baricitinib showed efficacy in NNS/CANDLE and SAVI patients with decreased daily...
     Safety: All patients experienced at least one adverse event. Three patients had serious ...

  20. [PMC] Oral Baricitinib in the Treatment of Cutaneous Lichen P...
     PASS: Disease=cutaneous lichen planus, N=12, Response=83.3%
     Efficacy: Early and sustained clinical response was observed with 83.3% of patients respon...
     Safety: No safety outcomes or adverse events were reported in the abstract or available ...

  21. [PMC] Baricitinib for refractory Takayasu arteritis: a prospe...
     PASS: Disease=Takayasu arteritis, N=10, Response=60.0%
     Efficacy: Baricitinib 4 mg daily achieved overall treatment response in 60% of refractory ...
     Safety: Treatment was generally well tolerated with no severe adverse events reported. O...

  22. [PMC] A retrospective study of the efficacy of JAK inhibitors...
     PASS: Disease=Rheumatoid arthritis-interstitial lung disease (RA-ILD), N=31, Response=83.9%
     Efficacy: JAK inhibitors demonstrated stability or improvement of RA-ILD in 83.9% of patie...
     Safety: No specific adverse events were reported in the study. Safety outcomes were not ...

--- Validation ---
  Successful: 20/22

================================================================================
 TAB 4: SCORING & PRIORITIZATION
================================================================================

  Scoring 20 extractions...

  Fetching market intelligence for each disease...
  (This requires web search for epidemiology & standard of care)
  Market data fetched for 10/20 diseases
